Chronic Dosing of Mice with a Transferrin Receptor Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Metabolism And Disposition

• Publication date

  2011-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/dmd.111.038349PMID 21502195PMCID PMC3127234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse

  2010cited by this paper
• Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier.

  2010cited by this paper
• Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey

  2009cited by this paper
• Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery

  2009cited by this paper
• Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse

  2009cited by this paper
• Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

  2008cited by this paper
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

  2008cited by this paper
• Cellular localization of GDNF and its GFRalpha1/RET receptor complex in the developing pancreas of cat

  2008cited by this paper
• GDNF fusion protein for targeted‐drug delivery across the human blood–brain barrier

  2008cited by this paper
• Reprint: Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys

  2007cited by this paper
• Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion

  2007cited by this paper
• Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys.

  2007cited by this paper
• Glial cell line-derived neurotrophic factor does not enter normal mouse brain

  2003cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002cited by this paper
• Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.

  2000cited by this paper
• GDNF family receptors in the embryonic and postnatal rat heart and reduced cholinergic innervation in mice hearts lacking Ret or GFRα2

  2000cited by this paper
• Expression and regulation of GFRalpha3, a glial cell line-derived neurotrophic factor family receptor.

  1998cited by this paper
• Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis.

  1996cited by this paper
• Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate

  1995cited by this paper

• Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein Pharmacokinetics.

  2026cites this paper
• Longitudinal pharmacokinetic and safety studies for dose optimization of a brain- penetrating erythropoietin for Alzheimer’s disease

  2025cites this paper
• Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease

  2025cites this paper
• Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

  2023cites this paper
• Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport

  2023cites this paper
• Engineering antibody and protein therapeutics to cross the blood–brain barrier

  2022cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport

  2022cites this paper
• Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor

  2021cites this paper
• Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy

  2021cites this paper
• Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies.

  2020cites this paper
• Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

  2020cites this paper
• Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice

  2020cites this paper
• Can Growth Factors Cure Parkinson's Disease?

  2020cites this paper
• Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

  2020cites this paper
• Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges

  2019cites this paper
• Targeting the transferrin receptor for brain drug delivery.

  2019cites this paper
• Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons.

  2019cites this paper
• Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.

  2018cites this paper
• Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.

  2017cites this paper
• Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

  2017cites this paper
• The Translational Significance of the Neurovascular Unit*

  2016cites this paper
• Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies

  2016cites this paper
• Targeted delivery of protein and gene medicines through the blood–brain barrier

  2015cites this paper
• Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the Blood–Brain Barrier

  2015cites this paper
• Transport of Protein and Antibody Therapeutics Across the Blood–Brain Barrier

  2015cites this paper
• Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors.

  2015cites this paper
• Blood–Brain Barrier Targeting of Therapeutic Lysosomal Enzymes

  2015cites this paper
• Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

  2015influential citation
• Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion.

  2014cites this paper
• Insulin receptor antibody‐iduronate 2‐sulfatase fusion protein: Pharmacokinetics, anti‐drug antibody, and safety pharmacology in Rhesus monkeys

  2014cites this paper
• Agile delivery of protein therapeutics to CNS.

  2014cites this paper
• IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.

  2013cites this paper
• Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.

  2013cites this paper
• Bispecific antibodies for delivery into the brain.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.

  2013cites this paper
• Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.

  2013cites this paper
• Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.

  2012cites this paper
• Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor

  2011cites this paper
• GENETIC AND PROCESS ENGINEERING FOR THE RECOMBINANT PRODUCTION OF PROTEIN THERAPEUTICS FOR THE TREATMENT OF CNS DISORDERS

  year unknowncites this paper